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TO THE EDITOR 
Acute lower GI bleeding is an uncommon but potentially life-threatening complication of Crohn's disease (CD) 
occurring in about 1.5% of cases (1, 2). The severity is judged on the basis of the need for transfusion of several 
units of blood. It represents a therapeutic challenge. A conservative approach has generally been advocated in 
view of the likelihood of spontaneous cessation of the bleeding. However, in some cases, particularly because of 
the risk of recurrence and multiple or diffuse bleeding lesions not allowing endoscopic treatment, there is a place 
for a drug with rapid mucosal healing potential (3-5). We describe two patients with severe bleeding caused by 
CD treated with infliximab. 
The first patient was a 28-yr-old white woman with a 3-yr history of CD involving the terminal ileum and the 
colon who was admitted for massive rectal bleeding. She also suffered from recurrent perineal fistula. Two days 
before admission, she developed profuse rectal bleeding. On admission, the blood count showed a hemoglobin of 
7.6 g/dl. Bleeding originating from upper GI tract or anal lesions was excluded. Colonoscopy showed a diffuse 
colonic involvement with multiple deep round or serpiginous ulcers located particulary in the cecum and me left 
colon. The colon contained a significant amount of blood, but the source of bleeding was not localized. After 
transfusion of two units of blood, oral budesonide (9 mg/day) and azathioprine (125 mg/day) were started. 
Because the patient continued to bleed, requiring three more units of blood and because of persistent fistula 
discharge, a treatment with infliximab infusion (5 mg/kg) was started. The patient left the hospital without 
recurrence of bleeding 4 days after the first infusion. She was readmitted 10 days later for a rebleeding and a 
hemoglobin of 6.1 g/dl. A proctosigmoidoscopy showed circumferential ulcers and copious amounts of blood 
and melena without identifying an obvious site of bleeding. After transfusion of five units of blood, a second 
infusion of infliximab (5 mg/kg), 14 days after the first one, was administered. The patient was discharged 
without bleeding recurrence. A third infusion was administered 1 month later. At this time, there was no 
bleeding recurrence, and proctosigmoidoscopy revealed a complete healing of colonie ulcerations. The patient 
remains disease free without evidence of bleeding 5 months later. 
The second patient was a 59-yr-old white woman with a 9-yr history of CD involving the colon who was 
admitted for rectal bleeding, diarrhea, and anemia. One month before admission, she noted increased diarrhea 
and frequent red blood per rectum. Medication on admission included oral steroids, metronidazole, and 
ciprofloxacine. On admission, the blood count showed a hemoglobin of 8 g/dl. Upper GI endoscopy was normal. 
Colonoscopy showed multiple deep round and large ulcers located in the right colon with blood ta the lumen, but 
no site of bleeding was identified. The rectum was normal. After transfusion of four units of blood, azathioprine 
(100 mg/day) was started and first infusion of infliximab (5 mg/kg) was given. Diarrhea decreased, and 
rectorragia disappeared 4 days after infusion. Four months later, the patient had a relapse of CD but without 
evident bleeding. She was successfuly treated with a new infusion of infliximab. 
The two cases show efficacy of infliximab in hemorragic forms of CD. This treatment allowed not only to 
control bleeding but also to scar underlying lesions. The primary treatment of severe lower GI bleeding in CD is 
determined by the severity and persistence of bleeding as well as the risk for recurrence. Localization of the site 
of bleeding is essential whether endoscopie therapy, surgery, or medical management is attempted. Endoscopie 
evaluation is preferable, if feasible, as it will provide a broader assessment of extent of disease as well as having 
a reasonable likelihood of identifying the site of bleeding with possible therapeutic intervention (2). If the acute 
bleeding ceases, an interval to attempt pharmacological therapy may be available, permitting treatment of the 
underlying CD. In our first case, severe acute bleeding resolved in two successive occasions a few days after 
infliximab infusion. This result may still be fortuitous. However, the fact that it occurred twice and the complete 
scarring of the lesion that was obtained later are arguments for a direct effect of infliximab, both in the early 
control of bleeding and in the absence of further recurrence. In our second case, mild-to-moderate bleeding had 
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lasted for more than 1 month. It stopped within 4 days after infliximab infusion and did not recur. Again, such 
rapid effect after a longstanding bleeding is an argument for a specific role of infliximab. 
In conclusion, our two cases show that new therapies such as infliximab, which may produce relatively rapid 
mucosal healing, may be beneficial and offer treatment alternative to surgery in either acute massive or chronic 
refractory bleeding in CD. 
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